Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Visceral Leishmaniasis
90%
Trypanosoma Brucei
79%
Trypanosoma Cruzi (T. cruzi)
76%
N-myristoyltransferase
65%
Chagas Disease
59%
Leishmania Donovani
51%
Drug Discovery
49%
Human African Trypanosomiasis
43%
Drug Target
43%
Kinetoplastid
36%
Mouse Model
36%
Phenotypic Screening
29%
Preclinical Candidate
25%
Trypanosomatids
25%
N-Myristoyltransferase Inhibitors
24%
High-throughput
23%
Mode of Action
23%
Methionyl-tRNA Synthetase
22%
Pyrazolo
22%
Naphthyridine
22%
Potential Treatments
22%
Anti-trypanosomatid Drugs
22%
Antitubercular Agents
22%
Oral Treatment
22%
Protozoan Parasites
22%
Pyrazole Sulfonamides
21%
New Drugs
21%
Kinetoplastid Parasites
21%
T. Brucei
21%
Leishmania
20%
Druggable Targets
18%
Scaffold Hopping
18%
Central Nervous System
18%
In Vivo Efficacy
17%
Potent Inhibitor
16%
Effective Compounds
16%
High-throughput Screening
16%
Small Molecules
15%
Proteasome Inhibition
15%
Antileishmanial Activity
14%
N-myristoylation
14%
Nifurtimox
13%
Mechanism of Action
13%
Active Compounds
13%
Penetrant
13%
Pharmacokinetic Properties
13%
Diamino
12%
Benznidazole
12%
Nitro
12%
Lead Optimization
12%
Medicinal Chemistry
11%
Molecular Targets
11%
Inhibitor Identification
11%
Pyrimidine
11%
Aspergillus Fumigatus
11%
Cyclin-dependent Kinase 12
11%
Cell Wall
11%
In Vivo Activity
11%
Delamanid
11%
Compound 8
11%
Pharmacological Validation
11%
Allosteric Binding Site
11%
Qi Site
11%
CYP51
11%
Amino
11%
1,6-Naphthyridines
11%
Structure Solution
11%
Indole-2
11%
Carboxamide Derivatives
11%
PA-824
11%
Open Resources
11%
1,2,3-Triazole-4-carboxamide
11%
R-enantiomer
11%
Metabolic Stability
11%
Chelator
11%
Inhibition Assay
11%
Inhibitor Evaluation
11%
Brain Penetrant
11%
Past-present
11%
Hit Rate
11%
Futures Past
11%
Binding Mode
11%
Imidazo
11%
Biochemical Characterization
11%
Infectious Diseases
11%
Divalent
11%
Protein Kinase
11%
Protease Inhibitors
11%
Inhibitor Discovery
11%
Antitrypanosomal Activity
11%
Biochemical Assay
11%
Triage
11%
Hydroxyl
11%
Cytochrome b
11%
Kinetochore
11%
Pyridine Scaffold
11%
Genetic Characterization
11%
5-Amino-1
11%
Neglected Diseases
11%
Further Development
10%
Disease Stage
10%
New Therapeutics
10%
Putative Drug Targets
9%
Tolerability
9%
Parasitic Infection
9%
Safe Treatment
9%
Parasite Burden
9%
Phenotypic Screen
9%
GlaxoSmithKline
8%
Kinetochore Protein
8%
Human Enzymes
8%
Leishmania Infantum
8%
Biochemical Studies
7%
Genetic Studies
7%
Lack of Information
7%
Brucei
7%
Drug pipeline
7%
Active Sites
7%
Leishmania Major
7%
Low Water Solubility
7%
Chronic Stage
7%
Screening Campaign
7%
Multi-target
7%
Methionine
7%
Drug Candidates
7%
Zn2+
6%
Therapeutic Target
6%
Developable
6%
Leishmaniasis
6%
Neglected Tropical Diseases
6%
Effective Treatment
6%
Cryo-EM Structure
6%
Protease
6%
Latin American Populations
5%
Glucuronidation
5%
Divalent Metal Cations
5%
Antitarget
5%
Benzomorpholine
5%
Thiazolidinone
5%
Pharmacokinetics
5%
Frontline Treatment
5%
Sequestration
5%
Physiologically Relevant
5%
Dundee
5%
Diversity Set
5%
Oral Exposure
5%
Endemic Region
5%
Aqueous Solubility
5%
Cytocidal
5%
Most Common Cause
5%
HERG
5%
Antileishmanial
5%
Peptide Substrate
5%
Target Deconvolution
5%
Latin America (LATAM)
5%
Acute Phase
5%
Dibasic
5%
Whole Cell
5%
Sulfonamide Antibiotics
5%
Cell Behavior
5%
Leishmania Tarentolae
5%
Chronic Phase
5%
Compound II
5%
Electron Transport Chain
5%
Cell-based Assay
5%
High-content Screening
5%
Therapeutic Potential
5%
Intracellular Parasites
5%
Compound Target
5%
Cytochrome bc1 Complex
5%
Physicochemical Properties
5%
Compound Library
5%
Causative Agents
5%
Binding Site
5%
Clinical Development
5%
Pharmacology, Toxicology and Pharmaceutical Science
Visceral Leishmaniasis
100%
Trypanosoma Brucei
80%
Diseases
64%
Chagas Disease
53%
Trypanosoma Cruzi
50%
Drug Discovery
49%
African Trypanosomiasis
46%
Kinetoplastida
45%
Leishmania donovani
43%
Mouse Model
42%
Trypanosomatidae
36%
Leishmania
33%
Sulfonamide
26%
Protozoon
24%
Methionine Transfer RNA Ligase
22%
Naphthyridine Derivative
22%
Carboxamide
22%
Binding Site
20%
Pyrazole
20%
Pharmacokinetics
17%
Divalent
16%
Phosphotransferase
16%
Proteasome
15%
Structure Activity Relationship
15%
Nifurtimox
15%
Hexachlorophene
14%
Leishmania Major
13%
Benznidazole
12%
Pharmaceutical Chemistry
11%
Delamanid
11%
Proteasome Inhibitor
11%
Amastigote
11%
Amitrole
11%
Pyrimidine Derivative
11%
Molecular Target
11%
Chelating Agent
11%
Side Effect
11%
Antitrypanosomal
11%
Protein Kinases
11%
Cyclin Dependent Kinase
11%
Transition Element
11%
Cytochrome B
11%
Lanosterol 14 Alpha-Demethylase
11%
Neglected Disease
10%
High-Throughput Screening
10%
Parasitosis
9%
Tolerability
9%
Fexinidazole
8%
Infection
8%
Clinical Trial
7%
Methionine
7%
Phenazone
6%
Cryo-Electron Microscopy
6%
Leishmaniasis
6%
Blood-Brain Barrier
6%
Nitroreductase
6%
Infectious Agent
6%
Proteinase
6%
Combination Therapy
6%
Therapeutic Window
5%
Coenzyme Q - Cytochrome C Reductase
5%
Enzyme Inhibition
5%
Antitarget
5%
High-Content Screening
5%
Zinc Ion
5%
Adenosine Triphosphate
5%
Leishmania tarentolae
5%
Cyclic AMP Dependent Protein Kinase
5%
Tropical Disease
5%
Metal Ion
5%
Leishmania infantum
5%
EC50
5%
Proteome
5%
Immunology and Microbiology
Visceral Leishmaniasis
52%
Trypanosoma Cruzi
51%
Kinetoplastida
44%
Leishmania donovani
40%
Chagas Disease
35%
Trypanosoma Brucei
33%
Leishmania
29%
Myristylation
28%
Proteasome
22%
Transfer RNA
22%
Binding Site
16%
Amastigote
16%
Protozoa
16%
Trypanosomatid
14%
Cytochrome
13%
Epimastigote
13%
Infectious Agent
11%
Qi
11%
Cell Wall
11%
Aspergillus fumigatus
11%
Enantiomer
11%
Solution Structure
11%
Kinetochore
11%
Mouse Model
8%
Whole Cell
7%
Parasite Load
7%
Peptides
7%
Methionine
7%
Leishmaniasis
6%
Cryo-Electron Microscopy
6%
Eukaryote
6%
Cell Assay
5%
Leishmania tarentolae
5%
Click Chemistry
5%
Central Nervous System
5%
Nuclear Magnetic Resonance Spectroscopy
5%
Life Cycle Stage
5%
Trypomastigote
5%
Amino Terminal Sequence
5%
Cell Labeling
5%
Crystal Structure
5%
Intracellular Transport
5%
Leishmania Major
5%
Leishmania infantum
5%
Axenic
5%
Cosmid
5%
Protein Degradation
5%
EC50
5%
Amino Acid
5%
Proteomics
5%
Enzyme Inhibition
5%